An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
Clinical trial NCT06021054 · COMPLETED
Trial details
- NCT number
- NCT06021054
- Sponsor
- Viridian Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-01
- Primary completion
- 2024-11-04
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.